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Tibolone expresses tissue-speciﬁc oestrogenic activity.
Oestrogenic eﬀects are seen on thermo-regulating cen-
tres, in the vagina and bone, but the breast and en-
dometrium are not stimulated. Tibolone belongs to a
new class of compounds, the Selective Tissue Estrogenic
Activity Regulators or STEARs. Two 3-OH metabolites
of tibolone are responsible for its oestrogenic activity.
Women using tibolone do not show an increase in
mammographic density, as is seen with oestrogen (E)
and progestagen (P) treatment, and the incidence of
breast pain is low. Data concerning the safety of tibo-
lone with regard to inducing breast cancer are incon-
clusive. Tibolone does not increase endometrium
proliferation as is seen with oestrogens. Tibolone itself
does not have the typical characteristics of compounds
binding to the estradiol receptor, but two 3-OH meta-
bolites of tibolone can activate the estradiol receptor.
Tibolone itself and a third metabolite, the D4-metabo-
lite, activate the progesterone and androgen receptors.
The conversion of tibolone into 3-OH tibolone is re-
versible. The hydroxymetabolites are the main active
metabolites circulating in the blood and are mainly
present as sulphated compounds. Oestrogenic stimula-
tion of the various tissues by tibolone depends therefore
on two inactivating, reversible systems; (1) the local
formation of progestogenic activity and (2) local desul-
phonation by sulphatase or sulphonation by sulpho-
transferase (for a review, see [1]). 2.5 mg of tibolone
prevents bone loss and climacteric complaints similar as
1 mg estradiol (for a review, see [2]). Safety has been
studied in various animal models. In the 7,12-
dimethylbenz(a)anthracene (DMBA)-rat model tibolone
prevented tumour development and in ovariectomised
monkeys, levels of the proliferation marker Ki67 was
not increased, whereas the combination of an E + P
resulted in a signiﬁcant increase. Clinical studies have
conﬁrmed that this marker is not increased by tibolone
treatment [3]. The explanation for this non-stimulating
eﬀect of tibolone is that tibolone and its metabolites
inhibit sulphatase and stimulate sulphotransferase. Ti-
bolone also stimulates apoptosis. Despite these en-
couraging results from preclinical and clinical studies, a
small increased risk of breast cancer was observed for
tibolone use in the Million Women (MW) study [4]. The
risk was the same as for that observed for oestrogen use
alone, but E + P combinations showed a signiﬁcantly
higher risk. The increased risk with the E + P combi-
nation was conﬁrmed in the Women Health Initiative
(WHI) study [5], but recently published data regarding
the oestrogen-only arm of this study did not show an
increased risk [6]. This suggests that no increase may be
expected in a randomised controlled trial for the tibo-
lone arm. The MW Study has been criticised in many
Editorials (for example, see [7]). A recent investigation
showed that tibolone is often selectively prescribed to
women at an increased risk of breast and endometrium
cancers [8], which may be another reason why in the
MW Study an increased risk was found.
Even more so than for the breast, oestrogenic stimu-
lation of the endometrium needs to be avoided. Proges-
tagenic compounds are therefore co-administered. A
two-year primate study showed that tibolone does not
induce the proliferation marker Ki67 in the en-
dometrium [9]. Various in vitro studies have shown that
tibolone induces progesterone-sensitive parameters, like
17-HSD type II and sulphotransferase. Sulphatase is
inhibited in endometrial cells, which also contributes
towards abolishing the oestrogenic activity in this tissue
[1].
Clinically, there is no diﬀerence between the eﬀects of
tibolone and continuous combined hormone therapy on
endometrial thickness, whereas the incidence of vaginal
bleeding with tibolone is lower than with continuous
combined hormone therapy. The endometrium remains
atrophic in most women treated with tibolone [2].
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In conclusion: tibolone expresses estrogenic activity
in a tissue-selective manner in post-menopausal women:
brain, vagina and bone are stimulated as with estrogens
but no stimulation of the breast and endometrium is
seen. Tibolone exerts these eﬀects by making use of
speciﬁc enzyme systems for metabolism and inactivation
of endogeneous hormones. Tibolone is the ﬁrst re-
presentative of the STEAR (Selective Tissue Estrogenic
Activity Regulator) class.
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